UPDATE: Goldman Sachs Downgrades BioXcel Therapeutics (BTAI) to Sell
Tweet Send to a Friend
(Updated - November 15, 2021 5:00 AM EST)
Goldman Sachs analyst Corinne Jenkins downgraded BioXcel Therapeutics (NASDAQ: BTAI) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Corinne Jenkins downgraded BioXcel Therapeutics (NASDAQ: BTAI) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
